| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total other income (expense), net | 6,880 | -7,931 | ||
| Net loss | -17,510 | -37,658 | ||
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -0.11 | -0.24 | ||
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.11 | -0.24 | ||
| Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic (in shares) | 158,313,290 | 155,437,281 | ||
| Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, diluted (in shares) | 158,313,290 | 155,437,281 | ||
Humacyte, Inc. (HUMAW)
Humacyte, Inc. (HUMAW)